Ranitidine is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives.




Short-term treatment of acute duodenal ulcer

Ranitidine – Tchaikapharma is efficient in short-term treatment of duodenal ulcer. Most patients are cured in four weeks.


Maintenance therapy of duodenal ulcer

The percentage of recurrence of duodenal ulcer in patients on maintenance therapy after healing of duodenal ulcer is lower than in subjects not given the maintenance dose of the medicinal product.

Short-term treatment of acute benign gastric ulcer

Most patients are cured in six weeks.

Maintenance therapy after remission of gastric ulcer

In patients with cured gastric ulcer, maintenance therapy is recommended with reduced Ranitidine – Tchaikapharma doses for prevention of ulcer recurrence.


Reflux esophagitis

Ranitidine – Tchaikapharma is used for treatment of reflux esophagitis, when standard therapy has produced no effect.


Treatment of pathologic conditions, running with the hiperacides.

Subject to medical prescription

Pharmaceutical form: 150 mg x 20 film-coated tablets

NHIF code: AF152          ICD: K20; K25.7; K26.7